What is the evidence for biologic switching in JIA?
Randomised controlled trial for guidance needed, say UK researchers
If a first biological DMARD is not helpful for patients with juvenile idiopathic arthritis (JIA), switching to a different class will not necessarily make a clinical difference, researchers say.